Trials / Unknown
UnknownNCT04638426
Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis
For 12 Weeks, the Multi Center, Randomized, Double Blinded, Placebo Controlled, Parallel, Dose-finding Clinical Study for the Therapeutic Exploration of Safety and Efficacy Assessment of HL237 Tablet in Patients With Rheumatoid Arthritis (Phase IIa)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 196 (estimated)
- Sponsor
- Hanlim Pharm. Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to determine the optimal dose of HL237 tablets in rheumatoid arthritis patients by comparing the efficacy and safety of the three dose groups of HL237 tablets and the control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HL237 tablet | Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day |
| DRUG | Placebo of HL237 tablet | Placebo of HL237, twice a day |
Timeline
- Start date
- 2020-09-10
- Primary completion
- 2021-05-01
- Completion
- 2021-08-01
- First posted
- 2020-11-20
- Last updated
- 2020-11-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04638426. Inclusion in this directory is not an endorsement.